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Background: Conjugation of sugars to 
chemicals by UGTs is a critical detoxification 
mechanism.  
Result: A single amino acid defines the 
differential sugar specificities of two related 
UGTs. 
Conclusion: Change of a single amino acid 
during primate evolution has generated a new 
capacity for small molecule glycosidation.  
Significance: Determinants of UGT sugar 
selectivity are currently poorly understood; 
novel glycosidation pathways may have 
important metabolic roles. 
SUMMARY 
Recent studies in this laboratory 
characterized the UGT3A family enzymes, 
UGT3A1 and UGT3A2, and showed that 
neither uses the traditional UGT co-substrate 
UDP-glucuronic acid. Rather, UGT3A1 uses 
N-acetylglucosamine as preferred sugar 
donor and UGT3A2 uses UDP-glucose. The 
enzymatic characterization of UGT3A 
mutants, structural modelling, and 
multispecies gene analysis have now been 
employed to identify a residue within the 
active site of these enzymes that confer their 
unique sugar preferences. An asparagine 
(N391) residue in the UGT signature 
sequence of UGT3A1 is necessary for 
utilization of UDP-N-acetylglucosamine. 
Conversely, a phenylalanine (F391) residue in 
UGT3A2 favors UDP-glucose use. Mutation 
of N391 to F in UGT3A1 enhances its ability 
to utilize UDP-glucose and completely 
inhibits its ability to use UDP-N-
acetylglucosamine. An analysis of homology 
models docked with UDP-sugar donors 
indicates that N391 in UGT3A1 is able to 
accommodate the N-acetyl group on C2 of 
UDP N-acetylglucosamine so that the 
anomeric carbon atom (C1) is optimally 
situated for catalysis involving H35. 
Replacement of N by F at 391 disrupts this 
catalytically-productive orientation of UDP 
N-acetylglucosamine but allows a more 
optimal alignment of UDP-glucose for sugar 
donation. Multispecies sequence analysis 
reveals that only primates possess UGT3A 
sequences containing the N391 residue, 
suggesting that other mammals may not have 
the capacity to N-acetylglucosaminidate small 
molecules. In support of this hypothesis, 
N391-containing UGT3A forms from two 
non-human primates were found to use UDP-
N-acetylglucosamine, while UGT3A isoforms 
from non-primates could not use this sugar 
donor. This work gives new insight into the 
residues that confer sugar specificity to UGT 
family members and suggests a primate-
specific innovation in glycosidation of small 
molecules. 
Glycosidation of lipophilic chemicals by 
the UDP glycosyltransferase  (UGT) 
superfamily is an important  detoxification 
pathway in all vertebrates (1). Glycosidation 
increases the water-solubility of the acceptor 
substrate, facilitating its excretion and/or 
otherwise altering its biological reactivity (2-5). 
Acceptors are structurally diverse and include 
steroid hormones, bile acids, biogenic amines, 
plant and bacterial metabolites, carcinogens and 
many therapeutic drugs (6). Thus glycosidation 
protects cells against exogenous toxins and 
accumulations of potentially toxic by-products 
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of metabolism. It can also play a role in 
modulating signalling pathways such as those 
mediated by steroid hormones. The glycosyl 
donor (co-substrate) is usually a UDP-hexose, 
typically UDP-glucuronic acid (UDP-GlcUA), 
UDP-glucose (UDP-Glc), UDP-xylose (UDP-
Xyl), UDP-galactose, (UDP-Gal) or UDP N-
acetylglucosamine (UDP-GlcNAc). During the 
conjugation reaction, the UDP--bond between 
UDP and the hexose moiety is converted into a 
-bond between the acceptor and the sugar via a 
SN2 mechanism, to form a -D-glycoside.  
In humans, four UGT families have been 
identified; UGT1, UGT2 (divided into sub-
families, 2A and 2B), UGT3 and UGT8 (6). The 
UGT1 enzymes are encoded by a single 
genomic locus on chromosome 2q37, which 
contains multiple enzyme specific exons 1A and 
a shared set of exons 2-5 (7). Differential 
promoter usage and splicing produces mRNAs 
for 9 separate UGT1A enzymes, each having a 
unique N-terminal domain encoded by an exon 
1A and an identical C-terminal domain encoded 
by exons 2-5. The UGT2 family is divided into 
the UGT2A and UGT2B sub-families. UGT2A1 
and 2A2 are encoded in a similar fashion to the 
UGT1A family, and have identical C-terminal 
domains encoded by a shared set of 5 exons. 
The remaining members of the UGT2 family are 
encoded by separate genes of 6 exons each, that 
are arrayed along chromosome 4q13 (6). The 
UGT3A family has two members denoted 
UGT3A1 (8) and UGT3A2 (9) that are arranged 
as a direct repeat on chromosome 5p13. The 
human UGT8 family contains only one gene 
UGT8A1 located on chromosome 4q26. 
The UGT1 and UGT2 enzymes use UDP-
GlcUA as their preferred sugar donor, although 
there are examples where other UDP-sugars are 
used. For example, UGT2B7 and UGT1A1 can 
utilize UDP-Glc, and UGT1A1 can use UDP-
Xyl (10-12). However, the activities of UGT1 
and UGT2 family enzymes with these alternate 
UDP-sugars are much lower than those with 
UDP-GlcUA, and are typically restricted to 
specific aglycone substrates. There is no 
evidence that UGT1 and UGT2 forms can use 
UDP-Gal or UDP-GlcNAc. UGT8 catalyses the 
transfer of galactose from UDP-Gal to ceramide 
in the production of glycosphingolipids; no 
other sugar donors or acceptors have been 
identified for this enzyme. Currently it is 
believed that UGT8 has an exclusively 
biosynthetic role and is not involved in 
detoxification (13). 
We recently characterized the substrate 
specificities of the UGT3A enzymes. In striking 
contrast to the UGT1 and UGT2 families, we 
found that neither UGT3A enzyme can utilize 
the prototypic UGT co-substrate UDP-GlcUA. 
UGT3A1 uses UDP-GlcNAc to conjugate 
several substrates including bile acids, steroids 
and bioflavones (8). This sugar selectivity is 
unique among vertebrate UGTs. UGT3A2 
preferentially utilizes UDP-Glc with a range of 
substrates including bioflavones and estrogens 
(9). The significance of these unusual sugar 
specificities remains unclear, although it is 
possible that the N-acetylglucosamine and 
glucose conjugates have important biological 
roles in vivo. UGT3A2, in particular, is 
expressed at very low levels in human liver, 
kidney and gastrointestinal tract suggesting that 
its major roles may be not in elimination of 
exogenous chemicals, but in endogenous 
metabolism.  
UGTs can be divided into two domains 
and typically show much greater sequence 
conservation within their C-terminal halves than 
their N-terminal halves. This is consistent with 
recognition of diverse aglycone substrates by 
the N-terminal domain and binding of the UDP-
sugar donor by the C-terminal domain. While 
sequence determinants of aglycone specificity 
have been identified by domain swapping and 
mutagenesis experiments, there has been limited 
progress in identifying residues involved in 
sugar specificity, in part because all UGT1 and 
2 enzymes preferentially use UDP-GlcUA and 
have only minor activities with other sugars. 
The recent discovery of differential sugar usage 
in the UGT3A family now provides a unique 
opportunity to address this issue. Using cross-
species sequence comparisons and site directed 
mutagenesis, we have identified a key residue in 
the putative sugar-binding domain that confers 
differential sugar specificities to the UGT3A 
proteins. We also provide evidence that the use 
of UDP-GlcNAc as a sugar donor is unique to 
primate UGT3A proteins. 





Materials- Radioactive and non-
radioactive UDP-sugars were obtained from the 
following: [C-14]UDP-glucose and -N-
acetylglucosamine (GE Healthcare), UDP-
glucose, -N-acetylglucosamine (Sigma-Aldrich). 
All other reagents and solvents were of 
analytical reagent grade. 
Production of UGT3A1 and UGT3A2 
mutants -  Site-directed mutagenesis was 
performed using human UGT3A1 and UGT3A2 
cDNAs encoded in the PCR2.1 vector and the 
Quick-Change mutagenesis method. N391 in 
UGT3A1 was mutated to F391 using the 





GGTAATCCCACCATGGG-3’. F391 in 
UGT3A2 was mutated to N391 using the 
following primers: forward 
5’-
CCCATGGTGGGGATCCCTCTCAATGGAG
ACCAGCCTGAAAACATGG-3’ and reverse 
5’-
CCATGTTTTCAGGCTGGTCTCCATTGAGA
GGGATCCCCACCATGGG-3’. The mutated 
products were verified by re-sequencing of the 
complete coding region and then subcloned into 
the pEF-IRESpuro6 expression vector which 
contains a puromycin resistance gene (14). 
Expression vectors were transfected into human 
embryonic kidney (HEK293T) cells and mixed 
cell populations stably expressing the mutant 
proteins were selected with puromycin (2 
g/ml). Lysates were prepared for assays in 
buffer containing 10 mM Tris, 1 mM EDTA pH 
7.6. 
 
Western blotting-   Proteins in lysates 
from HEK293T cells stably expressing wildtype 
and mutant UGT3A cDNAs were separated on 
SDS-polyacrylamide gels and transferred to 
nitrocellulose membranes as previously 
described (8,15). UGT3A wildtype and mutated 
proteins were detected with UGT3A1 and 
UGT3A2 antibodies generated previously (8,9) 
and a secondary goat anti-rabbit antibody 
conjugated with peroxidase (Neomarkers). 
Immunocomplexes were visualized with the 
Supersignal West Pico chemiluminescent kit 
(ThermoFisher Scientific) and quantified with 
the LAS4000 scanner (GE Healthcare).  
Enzyme assays-   For assays to assess co-
substrate preference, glycosidation reactions 
were performed as previously described (8). 
Briefly, incubations at 37
o
C for 1 hr, contained 
100 mM phosphate buffer, pH 7.5, 4 mM 
magnesium chloride, 100 µg HEK293T cell 
lysate, 200 µM aglycone and 2 mM [C-14]UDP-
sugar (0.1 Ci/mMole). Radioactive products 
were separated by thin layer chromatography (8) 
and quantified by exposure to a Phosphor 
Screen (Molecular Dynamics), which was 
scanned with a Typhoon 9400 scanner (GE 
Healthcare). Standard curves with known 
amounts of [C-14]UDP-sugar were constructed 
to quantify product formation. For comparisons 
of activities between lysates expressing UGT3A 
proteins, activities relative to the amount of 
UGT protein present in the lysate, as determined 
by Western blotting, were used.  
In silico modeling and docking- A human 
UGT3A1 homology model was constructed 
using FUGUE and ORCHESTRAR (SYBYL-X 
1.3, Tripos™). Homologs identified by FUGUE 
were refined against profile Hidden Markov 
Model (16) data constructed from the UGT3A1 
coding sequence. Crystal templates of grape 
UDP-glucose flavanoid 3-O glucosyltransferase 
(2C1X, 2C1Z, 2C9Z), glycosyltransferase 
UGT78G1 from Medicago truncatula (3HBF, 
3HBJ), and the cofactor-binding domain of 
UGT2B7 (2O6L) (17) were obtained from the 
Brookhaven Protein Data Bank (PDB) and 
sequence alignments refined using Cn3D 
relative to secondary structure. The highest 
acceptable inter-C distance between equivalent 
residues within a sequence conserved region 
was 1.5Å, with a RMS difference of 0.00001Å 
considered significant. Loops not modeled were 
found by loop threading all crystal structures of 
the HOMSTRAD database (SYBYL-X 1.3, 
Tripos™). Refinement of the model was 
achieved by undertaking independent 
minimizations of biopolymer hydrogens, side-
chains, the biopolymer omitting C carbons, 
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and finally the biopolymer as a whole. Each 
independent minimization allowed a maximum 
of 10,000 iterations using the method reported 
by Powell (18) with a termination gradient of 
<0.05 kcal/(mol)(Å). Automated docking of 
UDP-GlcNAc and UDP-Glc was achieved using 
the Surflex-Dock (SFXC) suite (SYBYL-X 1.3, 
Tripos™). Co-substrate docking was consensus 
scored (CScore) relative to protein interactions 
with hydrogen flexibility allowed. The relative 
strengths of co-substrate and protein covalent 
force fields were set to 1.00 and 0.10 
respecively. Ring flexibility was additionally 
allowed when generating the molecular co-
substrate fragments and minimized using a 
BGFS quasi-Newton method and an internal 
Dreiding force field (19). In silico mutants were 
generated by substiution of the desired amino 
acid. Substituted residues were energy 
minimized as a subset of the entire protein 
molecule using the Powell conjugate gradient 
method with an energy cutoff set to 0.05 
kcal/mol.Å. A ‘hot region’ of 6Å surrounding 
the substituted residue was established where 
the sidechains of all residues were minimized. A 
further ‘intermediate region’ of 12Å was 
generated to set the minimization environment 
without side-chain movement. Minimization by 
this method allowed changes in the energetic 
forces experienced by residues that either adjoin 
or neighbor the substituted amino acid. Distance 
measurements were collected to characterize the 
orientation of docked co-substrate poses. 
Distances were measured between the anomeric 
carbon (C1) of the co-substrate sugar moiety 
(i.e. the site of SN2 attack) and the N2 nitrogen 
of the catalytic base, H35. 
Cloning and expression of Non-human 
UGT3A cDNAs – Mouse Ugt3a1 and Ugt3a2 
cDNAs were obtained by reverse transcription 
of neonatal (up to one week old) mouse liver or 
kidney RNA. Briefly, first strand cDNA was 
synthesized with the Superscript
TM
 First Strand 
Synthesis System (Invitrogen). The Ugt3a1 
coding region was amplified from the cDNA 
using the forward primer, 5’-
CGGAATTCATGGCTGCACATCGGAGTTG
GC-3’ and the reverse primer, 5’-
CGGAATTCTTATGCCTGCTTGACCTTCCT
TG-3’. The mouse Ugt3a2 coding region was 
amplified using the forward primer, 5’- 
CGGAATTCATGGCAGCACATCGGCGTTG
G-3’ and the reverse primer, 5’-
CGGAATTCTTATGCCTCCTTGACCTTCGT-
3’. The initiation and stop codons in the forward 
and reverse primers respectively, are in italics. 
Gene nomenclature follows that of the NCBI 
Gene database. PCR was performed in a volume 
of 50 l with 200 ng cDNA, 0.5 M of the 
forward and reverse primers and the DNA 
polymerase, Pfu Turbo (Stratagene). The 
cycling parameters consisted of one cycle at 
95
o
C for 2 min, then 35 cycles of 95
o
C for 0.5 
min, 60
o
C for 0.5 min, 72
o
C for 2 min followed 
by a single 5-min cycle at 72
o
C. PCR products 
were excised from a 1% agarose gel, purified 
using the QIAquick gel extraction kit (Qiagen), 
and cloned into the pCR2.1 shuttle vector 
(Invitrogen) for sequencing. Both cDNAs were 
subcloned into the pEF-IRESpuro6 expression 
vector. 
 Full length cDNAs for chimp (Pan 
troglodytes) UGT3A1 (XM_526949), rhesus 
(Macaca mulatta) UGT3A1 (XM_001093373) 
and UGT3A2 (XM_001093598), Cow (Bos 
taurus) UGT3A2 (NM_001076087), and rabbit 
(Oryctolagus cuniculus) UGT3A 
(XM_002714108) were obtained from 
Genescript in the pUC57 shuttle vector. The 
cDNAs were excised and subcloned into the 
pEF-IRESpuro6 expression vector. Sequencing 
confirmed the identities of each clone.  
The human and chimp UGT3A2 proteins 
differ by only one amino acid (N309 in human 
is Y309 in chimp). To obtain a cDNA with the 
equivalent sequence to chimp UGT3A1, we 
performed site directed mutagenesis of the 
human UGT3A2 cDNA to introduce the chimp-
specific amino acid (Y309). The mutagenesis 




All non-human UGT cDNAs were 
transfected into HEK293T cells. Either 
transiently-expressing lysates, or lysates from 
puromycin-selected cell populations stably-
expressing the UGT of interest, were used in 
assays.  
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Analysis of endogenous Ugt3a gene 
expression in mouse tissue – To measure the 
levels of endogenous Ugt3a1 and Ugt3a2 
mRNAs in neonatal mouse livers and kidneys, 
we used quantitative RT-PCR with the 
following primers: Ugt3a1 forward 5’-
ACCGTGTGTCGCAAATTCTG-3’ and reverse 
5’-ACCTGGTATGATGAGTTTTCC-3’; 
Ugt3a2 forward 5’- 
TTCTCATGAGCTTCCTTTTCC-3’ and 
reverse 5’- GCGACACACGGCTTATCAC-3’. 
The raw data were converted to copy number 
using standard curves constructed from the 
cloned cDNAs. Data were then normalized to 
the mRNA abundance of the housekeeping gene 
ribosomal protein S26 (RPS26).  Reactions used 
the Qiagen SYBR-green reagent or GoTaq 
(Promega) and the Rotor-Gene 300 (Corbett 
Life Sciences) thermal cycler. 
 Preparation of mouse liver and kidney 
microsomes – Livers and kidneys from 2-3 
week old mice were snap frozen on dry ice. 
Microsomes were prepared according to (20) 




Functional analysis of residue 391 in 
human UGT3A1 and UGT3A2.  We have 
previously shown that UGT3A1 is unique 
among human UGTs in using UDP-GlcNAc as 
its preferred sugar donor (8), while human 
UGT3A2 utilizes UDP-Glc as its preferred co-
substrate (9). The UGT signature sequence is a 
30 amino acid region that is highly conserved in 
all UGTs and implicated in the binding of UDP-
sugars (see (6) and references therein). When 
the signature sequences of all human UGTs are 
aligned, the residue 391 is clearly divergent; this 
residue is asparagine (N) in UGT3A1 and 
phenylalanine (F) in all other human UGTs 
including UGT3A2 (Figure 1). We hypothesized 
that N391 may be important for conferring the 
unique ability of human UGT3A1 to utilize 
UDP-GlcNAc. 
Site-directed mutagenesis was used to 
substitute N391 in UGT3A1 with phenylalanine 
(N391F), and conversely to substitute F391 in 
UGT3A2 with asparagine (F391N). The stable 
expression of both mutated proteins in 
HEK293T cells was confirmed using western 
blotting (not shown). The activity of both 
mutated and wildtype proteins was examined 
using either UDP-Glc or UDP-GlcNAc and the 
aglycone substrate genistein. Genistein was 
selected because it was previously found to be a 
good substrate for both UGT3A1 and UGT3A2 
with their preferred sugar donors (8,9,21).  
Using sensitive assays for glycosidation, 
we observed that wildtype UGT3A1 in fact has 
a weak inherent capacity to conjugate glucose to 
genistein (see Supplemental Figure 1). Mutation 
of UGT3A1 N391 to F391 (N391F) 
dramatically enhanced glucosidation activity 
and simultaneously abolished activity with 
UDP-GlcNAc (Table 1). Mutation of UGT3A2 
F391 to N391 (F391N) reduced the enzyme’s 
activity with UDP-Glc by around 150-fold 
(Table 1); however, it did not confer activity 
with UDP-GlcNAc.  
Structure modelling and UDP-sugar 
docking. To examine the structural basis 
underpinning the importance of residue 391, 
homology models of UGT3A1 and the 
UGT3A1-N391F mutant were generated and 
docked with UDP-GlcNAc or UDP-Glc (Figs 2 
and 3). The docking of UDP-GlcNAc to 
UGT3A1 revealed direct side-chain H-bonding 
interactions from E377 to both hydroxyl 
hydrogens of the ribose, N373 to two oxygens 
of the diphosphate, H369 and Q394 to the 3’ 
hydroxyl oxygen of the ribose, and D393 to the 
4’ hydroxyl hydrogen of the sugar moiety. 
Numerous main-chain (both nitrogen and 
oxygen) H-bonding interactions provided 
further stabilization of the UDP moiety, these 
include: L352 and Q354 to uracil, and Q372, 
N373, and S374 to the diphosphate. W351 was 
in a position to form - and - orbital 
interactions with the uracil. The residues 
utilized in orientating UDP-GlcNAc for 
nucleophillic attack by the aglycone are located 
within the UGT signature sequence (Figure 2). 
All UGTs appear to have a histidine (H35 
in UGT3A1) which acts as a catalytic base to 
facilitate activation of the sugar-acceptor group 
on the aglycone by deprotonation for subsequent 
nucleophilic attack on the anomeric carbon (C1) 
of the sugar donor (22). When UDP-GlcNAc is 
docked into UGT3A1 (Figure 3A), the distance 
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between the catalytic histidine and C1 is 4.02Å, 
which increases to 6.21 Å  when UDP-Glc is 
docked into the protein (Figure 3B). In contrast, 
when UDP-GlcNAc or UDP-Glc are docked 
into UGT3A1-F391 (Figures 3C and 3D) the 
distances are 6.18Å and 3.60Å, respectively. 
Hence, the UGT3A1 proteins that are most 
active with their respective sugar donors (i.e. 
UGT3A1 with UDP-GlcNAc and UGT3A1-
F391 with UDP-Glc) have shorter distances 
between the catalytic histidine and C1, 
compared to the UGT3A1 protein/UDP-sugar 
combinations that have little activity (i.e. 
UGT3A1 with UDP-Glc, and UGT3A1-F391 
with UDP-GlcNAc). 
Cloning and functional analysis of mouse 
Ugt3a1 and Ugt3a2.   We examined UGT3A 
sequences in the genomes of multiple species to 
determine when the N391 residue may have 
evolved. In all species examined, UGT3A genes 
were located in regions of shared synteny, 
including the flanking genes LMBR1 domain 
containing-2 (LMBRD2) and calcyphosine-like 
(CAPSL). These flanking genes were used as 
markers to guide our identification of UGT3A 
genes and pseudogenes in each genome. We 
found that the human, chimp, gorilla, baboon, 
macaque, marmoset and tarsier genomes each 
encode one UGT3A form with an N391 residue 
and one with an F391 residue (Figure 4). The 
orang-utan genome appears to encode only one 
UGT3A form and that bears the N391 residue. 
The genomes of the gibbon, bushbaby 
(otolemur) and mouse lemur, and of non-
primates including mouse, rat, rabbit, dog, cow, 
horse, panda, elephant, and platypus contained 
one or more UGT3A genes that each encodes 
the F391 residue (or in some cases L391) and no 
genes that encode the N391 residue. In general, 
the signature sequences of primate UGT3A 
paralogues show less similarity to one another 
than those of the non-primate UGT3A 
paralogues. For example, the human UGT3A1 
and UGT3A2 proteins are only 82% identical 
within their signature sequences while the 
mouse Ugt3a1 and Ugt3a2 are 95% identical 
within their signature sequences. 
Given the effect of the UGT3A1-N391F 
mutation on sugar preference, we hypothesized 
that only genes that encode N391 may 
efficiently utilize UDP-GlcNAc as a sugar 
donor in conjugation reactions. To test this 
hypothesis we first cloned mouse Ugt3a1 and 
Ugt3a2 cDNAs and examined their sugar 
specificity in the heterologous HEK cell 
expression system. 
As shown in Table 2, mouse Ugt3a1 was 
active with 4-methylumbelliferone (4-MU), and 
ursodeoxycholic acid (UDCA) using UDP-Glc 
as the sugar donor. However, it showed no 
activity toward either substrate with UDP-
GlcNAc.  Mouse Ugt3a2 was also able to 
conjugate 4-MU and UDCA with UDP-Glc, 
although to a lesser extent than Ugt3a1, and it 
was also inactive with UDP-GlcNAc.  
The arrangement of the UGT3A genes and 
their immediate neighbours in the human 
genome is LMBRD2 - UGT3A2 - UGT3A1 – 
CAPSL. However, in the public mouse genome 
databases, the name Ugt3a1 has been assigned 
to the gene most proximal to Lmbrd2 (e.g. 
Lmbrd2 - Ugt3a1 - Ugt3a2 – Capsl) (see (21).  
The products of the mouse Ugt3a1 and Ugt3a2 
genes show the same degree of sequence 
similarity to the human UGT3A1 product. Based 
on genomic position, we suggest that mouse 
Ugt3a2 is in fact likely to be the homologue of 
human UGT3A1. In support of this notion, it 
was found that mouse Ugt3a1 shows a similar 
pattern of expression to human UGT3A2 and 
that mouse Ugt3a2 expression is more similar to 
that of human UGT3A1. Specifically, the 
expression of mouse Ugt3a2 is vastly higher in 
liver and kidney than that of Ugt3a1 (Figure 
4A). We have previously shown that human 
UGT3A1 mRNA is abundant in human liver and 
kidney while human UGT3A2 mRNA is barely 
detectable in liver and very low in kidney (8,9).  
Given the likelihood that mouse Ugt3a2 is 
the homologue of human UGT3A1; we sought 
additional aglycone substrates for this enzyme 
to confirm its apparent inability to use UDP-
GlcNAc. Several bile salts and related chemicals 
were investigated. Hyodeoxycholic acid 
(HDCA) was identified as the aglycone with 
which mouse Ugt3a2 had highest glucosidation 
activity. However, even with this substrate, 
Ugt3a2 showed no activity with UDP-GlcNAc 
as sugar donor (Figure 5B). This result further 
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supports the idea that both mouse Ugt3a 
enzymes can utilize only UDP-Glc.  
To assess whether mouse may have any 
capacity for N-acetylglucosaminidation of small 
molecules, we tested microsomal preparations 
of mouse liver and kidney for endogenous 
conjugation activity using UDP-Glc or UDP-
GlcNAc and a variety of aglycones including 
mycophenolic acid (MCA), HDCA, hesperetin, 
and 4-MU. Only glucose conjugates were 
detected (Figure 5C), further supporting the idea 
that the mouse does not express an UDP-N-
acetylglucosaminyltransferase.  
 
Activities of chimp, rhesus, cow and rabbit 
UGT3A proteins 
To further test our hypothesis that only 
genes that encode N391 may utilize UDP-
GlcNAc as a sugar donor in conjugation 
reactions, we obtained an assortment of clones 
encoding UGT3A enzymes from various 
primate and non-primate species and expressed 
them in HEK293T cell culture. Activity was 
examined using a variety of aglycone substrates 
and both UDP-Glc and UDP-GlcNAc as sugar 
donor. All recombinant UGT3A enzymes were 
catalytically active. However, only those 
UGT3A enzymes that contain the N391 residue 
were able to use UDP-GlcNAc as sugar donor 
(Figure 6). Those with a phenylalanine in this 





UDP-GlcUA recognition by human UGTs 
has been investigated by several laboratories 
since early photoaffinity labelling experiments 
suggested a binding site between amino acids 
299 and 466 (23). Several residues within the 
UGT signature sequence including H371 and 
E379 (numbering from UGT1A6) (24) and the 
DQ motif that marks the end of the UGT 
signature sequence (D393, Q394 in UGT1A10) 
(25) have been shown to play important or 
essential roles in UDP-GlcUA binding (25). In 
contrast, there has been little progress in 
understanding the structural basis of differential 
sugar recognition by UGTs, as most mammalian 
UGTs show only minor activities with sugars 
other than UDP-GlcUA. Characterization of the 
divergent sugar preferences of the UGT3A 
enzymes provided us with an opportunity to 
identify residues that may confer selectivity for 
different UDP-sugars. 
By analysis of UGT3A family enzymes 
we have shown that N391 within the signature 
sequence of UGT3A1 is essential for its 
capacity to utilize UDP-GlcNAc as a sugar 
donor: substituting phenylalanine at this 
position blocks its ability use UDP-GlcNAc and 
instead promotes utilization of UDP-Glc. 
Docking of various sugars into a homology 
model of wildtype UGT3A1 suggests that the 
catalytic histidine is significantly closer to the 
anomeric carbon of UDP-GlcNAc than UDP-
Glc, which likely explains its greater activity 
with UDP-GlcNAc than with UDP-Glc.   
While the N391F mutation altered the 
sugar preference of UGT3A1, the level of 
activity of UGT3A1-N391F with UDP-Glc was 
lower than that of UGT3A2 with UDP-Glc, or 
of wildtype UGT3A1 with UDP-GlcNAc. This 
suggests that additional residues determine the 
efficiency with which the preferred sugar is 
used. We attempted to identify such residues by 
swapping signature sequences and adjacent 
segments between UGT3A1 and UGT3A2 (not 
shown). Some of these chimeric enzymes were 
poorly expressed suggesting that they may be 
structurally unstable. However, even among the 
variant UGT3A1 proteins that were efficiently 
expressed, we did not find any that had greater 
activity with UDP-Glc than the UGT3A1-
N391F mutant (not shown). Thus the residue at 
position 391 is the major contributor to sugar 
specificity within the signature sequence and 
other residues that influence enzymatic activity 
are likely to be located distal to the signature 
sequence.  
Plant UGTs are extremely diverse and 
have a broader range of UDP-sugar preferences 
than mammalian UGTs. Several studies 
involving plant UGTs have identified residues 
that contribute to sugar specificity, but none of 
these directly overlap with F391 in mammalian 
UGTs.  Kubo et al (26) found that the Q within 
the DQ motif (Q394 in human UGT3A1) is 
conserved in plant and animal UDP 
glucuronosyltransferases and 
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glucosyltransferases, but that this residue is H in 
plant and animal UDP galactosyltransferases. 
Mutation of this residue from H to Q in a plant 
UDP galactosyltransferase lowered the Km of 
this enzyme for UDP-Glc approximately 40-fold 
suggesting that Q plays a role in glucose 
recognition. The complementary mutation of Q 
to H in a plant UDP glucosyltransferase 
impaired its ability to use UDP-Glc but did not 
confer activity with UDP-Gal (26). Moreover, 
mutation of the Q residue to H in another plant 
glucosyltransferase VvGT1 abolished activity 
(27). The D and Q residues were predicted to 
interact directly with the hydroxyl groups of the 
sugar moiety of UDP-Glc (27), a similar 
conclusion to that previously drawn for the DQ 
motif in binding of UDP-GlcUA (25).  
Human UGT3A1 and UGT3A2 share the 
DQ (D393, Q394) motif with all other 
mammalian UGTs, suggesting that they are not 
important for sugar specificity. However, the 
two residues immediately after Q394 are 
divergent between UGT3A1 and other 
mammalian UGTs (see Figure 1). We found that 
mutation of these two residues in UGT3A1 
impaired protein stability and activity with both 
UDP-GlcNAc and UDP-Glc (not shown). Thus 
the carboxyl-terminal end of the signature 
sequence may be involved indirectly in both 
sugar binding and catalysis by determining 
correct folding of UGT3A enzymes.  
As well as identifying residues in UGT3A 
enzymes that confer specificity for UDP-
GlcNAc or UDP-Glc, it is interesting to 
consider what sequence or structural features 
may preclude their use of UDP-GlcUA. 
Residues that confer UDP-GlcUA specificity 
have been examined using site-directed 
mutagenesis and protein modelling of 
BpUGT94B1, a UGT from red daisy (Bellis 
perennis) that conjugates glucuronic acid to 
flavonoids. This analysis identified an arginine 
outside of the signature sequence (R25) as 
crucial for activity with UDP-GlcUA, with R25 
mutants exhibiting dramatically reduced activity 
with UDP-GlcUA, and 3-fold increased activity 
with UDP-Glc (28). A conserved arginine is 
found in the corresponding position relative to 
the mature N-terminus of all human UGTs of 
the UGT1 and UGT2 families. However, in 
UGT3A1 and UGT3A2 this residue is histidine 
(H49). This may support the notion that arginine 
at this position is important for utilization of 
UDP-GlcUA. It should be noted, however, that 
UGT8, which is only known to use UDP-Gal, 
also has an arginine at this position; thus the 
function of this residue is likely to be context 
dependent. 
Is UDP-GlcNAc conjugation by UGT3A1 
a primate innovation? Our cross-species 
genomic analysis indicates that N391-containing 
forms of the UGT3A family occur only in 
primates. Experimentally, we found that primate 
UGT3A1 proteins that contain the N391 residue 
(human, chimp and rhesus) were all capable of 
N-acetylglucosaminidation. In contrast, all of 
the UGT3A proteins from non-primates that we 
tested (cow, rabbit and mouse) lacked the N391 
residue and were incapable of N-
acetylglucosaminidation. Although it is not 
feasible to test all species, this sampling 
provides strong support for the idea of a primate 
specific UGT3A1 enzymatic activity. 
Additional circumstantial evidence for this 
notion is provided by the observations that 1) 
the signature sequences of primate UGT3A gene 
paralogues generally show lower sequence 
identity than non-primate paralogues, 
suggesting that the primate UGT3A enzymes 
are more functionally divergent, and 2) many 
non-primates have only one Ugt3a family gene 
(e.g. rat, rabbit, and elephant). 
It is difficult to determine when the 
capacity for N-acetylglucosaminidation may 
have first emerged. Lemurs lack a N391-
containing UGT3A isoform, suggesting that this 
residue may have first appeared around the time 
that haplorhini and strepsirrhini primates 
diverged 63 million years ago. However, both 
lemur genomes have lower-coverage (less than 
2x) than the other primate genomes. Thus, 
future analyses of higher resolution genome 
assemblies may change this conclusion. There is 
also evidence for selective gene loss in some 
primates: e.g. gibbon and orang-utan have only 
one UGT3A gene (both of these genomes have 
5-6x coverage). Similarly we have observed that 
the entire UGT3A family is absent in sequenced 
bird genomes although present in reptiles and 
some species of fish (unpublished observations).  
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Identification of endogenous substrates for 
human UGT3A enzymes as well as their 
developmental expression patterns may provide 
insight into the significance of primate 
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 FIGURE LEGENDS 
 
Figure 1. Alignment of the UGT signature sequences of all human UGTs: the residue at position 391 is 
divergent in human UGT3A1.  
 
Figure 2. Docked UDP-GlcNAc (sticks) positioned for productive SN2 nucleophilic attack. Stabilization 
of the uridine, diphosphate, and sugar substituents of the cofactor involves hydrogen bonding 
interactions with highly conserved residues of the UGT signature sequence (cartoon). Bonding 
interactions are observed from L352/Q354/E377 to the uridine, Q372/N373/S374 to the diphosphate, 
and H369/Q394 to the sugar moiety. 
 
Figure 3. Energetically favoured poses of cofactor after automated in silico docking.  (A) UDP-GlcNAc 
with wild-type UGT3A1, (B) UDP-Glc with wild-type UGT3A1, (C) UDP-GlcNAc with 
UGT3A1(N391F) mutant, and (D) UDP-Glc with UGT3A1(N391F) mutant 
 
Figure 4. Alignment of UGT3A signature sequences from multiple primate and non-primate species. 
Genomes were accessed using the NCBI and Ensembl genome browsers. Accession numbers are given 
for each database where the gene had been annotated. BLAST analysis was also used to identify all 
possible homologues within each locus. Pairwise comparisons were performed using CLUSTALW and 
the percentage identity between the signature sequences of paralogous genes is given to the right of the 
table. For dog the percentage identity is given as the mean of the three pairwise comparisons. 
 
Figure 5. A) Analysis of Ugt3a1 and Ugt3a2 mRNA levels in neonatal mouse liver and kidney by 
quantitative RT-PCR. Data were analysed using a standard curve for each gene and normalized to the 
housekeeping gene RPS26. B) Analysis of mouse Ugt3a2 enzymatic activity with its preferred aglycone 
substrate hyodeoxycholic acid (HDCA) and either UDP-Glc or UDP-GlcNAc as sugar donor. Assays 
were chromatographed and visualized by autoradiography. The arrow indicates the HDCA glucoside, 
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the asterisk indicates endogenous glycosidation activities in HEK293T cells. n.c. – negative control 
HEK293T lysate. C) Analysis of endogenous glucosidation and N-acetylglucosaminidation activities in 
mouse liver and kidney microsomal preparations. Assays were performed using a range of aglycone 
substrates and either UDP-Glc or UDP-GlcNAc as sugar donor, and analysed as in B).  
 
Figure 6. Analysis of the enzymatic activities of various primate and non-primate UGT3A isoforms 
using preferred aglycone substrates and either UDP-Glc or UDP-GlcNAc as sugar donor. Assays were 
chromatographed and the glycosides products visualized by autoradiography. Human UGT3A1 and 3A2 
served as positive controls. 
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Table 1. Activities of wildtype and mutated forms of human UGT3A1 and UGT3A2 with genistein and 
either UDP-Glc or UDP-GlcNAc as sugar donor.  




UGT3A1 wt 1.75 +/- 0.05 65.74 +/- 13.13 
UGT3A1 N391F 15.03 +/- 1.33 nd 
UGT3A2 wt 137.65 +/- 6.59 nd 
UGT3A2 F391N 0.82 +/- 0.08 nd 





Table 2. Activities of wildtype mouse Ugt3a1 and Ugt3a2 with various aglycone substrates and either 
UDP-Glc or UDP-GlcNAc as sugar donor.  
Protein variant Activity with UDP-
Glc (pmol/min/mg) 
Activity with UDP- 
GlcNAc (pmol/min/mg) 
 4MU UDCA 4MU UDCA 
mUGT3A1 3.08 5.56 nd nd 
mUGT3A2 4.77 2.84 nd nd 
nd = not detected 
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Figure 2 
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